GlycoMimetics (GLYC) Competitors

RenovoRx (NASDAQ:RNXT) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.

Does the MarketBeat Community believe in RNXT or GLYC?

GlycoMimetics received 303 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 57.53% of users gave GlycoMimetics an outperform vote while only 56.00% of users gave RenovoRx an outperform vote.

Company	Underperform	Outperform
RenovoRx	Outperform Votes 14 56.00%	Underperform Votes 11 44.00%
GlycoMimetics	Outperform Votes 317 57.53%	Underperform Votes 234 42.47%

Does the media prefer RNXT or GLYC?

In the previous week, RenovoRx had 7 more articles in the media than GlycoMimetics. MarketBeat recorded 12 mentions for RenovoRx and 5 mentions for GlycoMimetics. RenovoRx's average media sentiment score of 0.99 beat GlycoMimetics' score of 0.30 indicating that RenovoRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlycoMimetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals have more ownership in RNXT or GLYC?

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are owned by institutional investors. 9.1% of RenovoRx shares are owned by insiders. Comparatively, 8.7% of GlycoMimetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has preferable earnings and valuation, RNXT or GLYC?

RenovoRx has higher revenue and earnings than GlycoMimetics. RenovoRx is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$240K	207.24	-$10.23M	-$0.40	-3.40
GlycoMimetics	$10K	1,071.23	-$37.88M	-$0.46	-0.36

Do analysts prefer RNXT or GLYC?

RenovoRx presently has a consensus price target of $7.25, indicating a potential upside of 433.09%. Given RenovoRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe RenovoRx is more favorable than GlycoMimetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
GlycoMimetics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is RNXT or GLYC more profitable?

RenovoRx's return on equity of -205.96% beat GlycoMimetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	N/A	-205.96%	-110.01%
GlycoMimetics	N/A	-230.74%	-177.39%

Which has more volatility & risk, RNXT or GLYC?

RenovoRx has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Summary

RenovoRx beats GlycoMimetics on 11 of the 17 factors compared between the two stocks.